Search

Your search keyword '"Sarah Parisi"' showing total 4 results
Start Over Author "Sarah Parisi" Publisher american society of clinical oncology (asco)
4 results on '"Sarah Parisi"'

1. Pharmacological interaction and side effects in oncohaematology: a retrospective observational study

Author

Elena Tenti, Giovanni Marconi, Nicoletta Testoni, Claudia Venturi, Cristina Papayannidis, Antonella Padella, Sarah Parisi, Chiara Sartor, Emanuela Ottaviani, Francesco Emanuele Antonio Brera, Giovanni Martinelli, Stefania Paolini, Maria Chiara Fontana, Giorgia Simonetti, Viviana Guadagnuolo, Andrea Casadei Gardini, Carmen Baldazzi, Tenti, Elena, Gardini, Andrea Casadei, Papayannidis, Cristina, Marconi, Giovanni, Simonetti, Giorgia, Parisi, Sarah, Paolini, Stefania, Sartor, Chiara, Ottaviani, Emanuela, Venturi, Claudia, Fontana, MARIA CHIARA, Padella, Antonella, Guadagnuolo, Viviana, Testoni, Nicoletta, Baldazzi, Carmen, Brera, Francesco, and Martinelli, Giovanni

Subjects
Drug, Cancer Research, medicine.medical_specialty, business.industry, media_common.quotation_subject, fungi, food and beverages, Retrospective cohort study, Oncology, Pharmacokinetics, Internal medicine, Pharmacodynamics, medicine, sense organs, skin and connective tissue diseases, business, oncoematologia, farmacologia, media_common
Abstract

e18235Background: Patients affected by oncohaematology pathology follow multiple therapies that can contribute to the drug interactions resulting in change in pharmacokinetics or pharmacodynamics o...

Published
2016

2. Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML)

Author

Maria Chiara Abbenante, Marco Manfrini, Viviana Guadagnuolo, Elena Tenti, Antonella Padella, Claudia Venturi, Giorgia Simonetti, Andrea Ghelli Luserna di Rorà, Emanuela Ottaviani, Cristina Papayannidis, Sarah Parisi, Elisa Zuffa, Eugenia Franchini, Giovanni Martinelli, Chiara Sartor, Silvia Lo Monaco, Maria Chiara Fontana, Stefania Paolini, Valentina Robustelli, Giovanni Marconi, Franchini, Eugenia, Papayannidis, Cristina, Marconi, Giovanni, GHELLI LUSERNA DI RORÀ, Andrea, Simonetti, Giorgia, Guadagnuolo, Viviana, Padella, Antonella, Robustelli, Valentina, Zuffa, Elisa, Abbenante, Mariachiara, Venturi, Claudia, Manfrini, Marco, Parisi, Sarah, Paolini, Stefania, Sartor, Chiara, LO MONACO, Silvia, Tenti, Elena, Fontana, MARIA CHIARA, Ottaviani, Emanuela, and Martinelli, Giovanni

Subjects
Cancer Research, business.industry, Biologia molecolare, Myeloid leukemia, Internal tandem duplication, Newly diagnosed, Disease, Oncology, hemic and lymphatic diseases, Flt3 mutation, Cancer research, Medicine, business, Flt3 gene, Tyrosine kinase, Survival analysis
Abstract

e18521Background: AML is a disease with a high number of various mutations and genomic abnormalities; most of them have a proved prognostic value. We focused on FLT3 gene, which shows a high hetero...

Published
2016

3. Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis

Author

Marco Manfrini, Maria Chiara Abbenante, Nicoletta Testoni, Silvia Lo Monaco, Giovanni Marconi, Simona Soverini, Stefania Paolini, Giorgia Simonetti, Antonella Padella, Elena Tenti, Andrea Ghelli Luserna di Rorà, Viviana Guadagnuolo, Maria Chiara Fontana, Giovanni Martinelli, Anna Maria Ferrari, Cristina Papayannidis, Carmen Baldazzi, Sarah Parisi, Chiara Sartor, Fontana, MARIA CHIARA, Marconi, Giovanni, Papayannidis, Cristina, Guadagnuolo, Viviana, LO MONACO, Silvia, Ferrari, Anna, Tenti, Elena, GHELLI LUSERNA DI RORÀ, Andrea, Simonetti, Giorgia, Abbenante, Mariachiara, Parisi, Sarah, Paolini, Stefania, Sartor, Chiara, Padella, Antonella, Soverini, Simona, Manfrini, Marco, Testoni, Nicoletta, Baldazzi, Carmen, and Martinelli, Giovanni

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chromothripsis, business.industry, Myeloid leukemia, Cancer, Karyotype, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, karyotype, chromothripsis, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business, neoplasms, 030217 neurology & neurosurgery
Abstract

7044Background: Genomic alterations are proved to initiate cancer and related to prognosis in AML. We tested 101 consecutive AML patients (pts) at diagnosis to find prognostic implications of new g...

Published
2016

4. Correlation of RASGRP1/APTX ratio with clinical response and survival in AML patients treated with tipifarnib-bortezomib combination

Author

Stefania Paolini, Emanuela Ottaviani, Anna Candoni, Michele Baccarani, Daniela Cilloni, Cristina Papayannidis, G. Saglio, Giovanni Martinelli, Antonio Curti, Ilaria Iacobucci, and Sarah Parisi

Subjects
Cancer Research, medicine.medical_specialty, Treatment response, business.industry, Bortezomib, aptX, Cytogenetics, Gastroenterology, Surgery, Correlation, medicine.anatomical_structure, Oncology, Internal medicine, Toxicity, medicine, Tipifarnib, Bone marrow, business, medicine.drug
Abstract

6550 Background: We conducted a phase I-II study aiming to assess efficacy and toxicity of tipifarnib-bortezomib treatment in elderly AML patients. RASGRP1/APTX genetic ratio, which is associated with treatment response in patients treated with tipifarnib alone, was tested. Methods: Eighty patients were enrolled with secondary-AML: 14 had high-risk cytogenetics; 42 were previously untreated. Seventy-five patients were treated. Results: Nine patients achieved complete remission (CR), 1 patient obtained a partial response (PR) and in 2 cases an hematological improvement (HI) was documented for an overall response rate (ORR) of 19%. Median time to response was 112 days, corresponding to 4 cycles (range 2-14). Marrow response (CR+PR) was significantly associated with overall survival (OS) (p < 0.0001). RASGRP1/APTX was evaluated before treatment initiation on bone marrow (BM), peripheral blood (PB) or both. The median RASGRP/APTX value on BM was 15.3 (15-19.8) in responder patients and 2.2 (0.5-25.9) in non r...

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results